H
Hao Xie
Researcher at Mayo Clinic
Publications - 61
Citations - 910
Hao Xie is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 15, co-authored 52 publications receiving 609 citations. Previous affiliations of Hao Xie include Cleveland Clinic Lerner College of Medicine & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Wen Wee Ma,Hao Xie,Gerald J. Fetterly,Laura Pitzonka,Amy Whitworth,Charles LeVea,John Wilton,Krystin Mantione,Sarah A Schihl,Grace K. Dy,Patrick McKay Boland,Renuka Iyer,Wei Tan,William E. Brady,Robert M. Straubinger,Alex A. Adjei +15 more
TL;DR: Dovitinib 300 mg daily is the recommended dose when combined with gem citabine and capecitabine, achieving clinically relevant plasma concentrations and the study combination demonstrated encouraging efficacy signals in advanced pancreatic cancer.
Journal ArticleDOI
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies.
Hao Xie,Alex A. Adjei +1 more
TL;DR: The literature is reviewed from several perspectives including the design, pharmacology, and mechanism‐based toxicities of antibody‐drug conjugates, currently in clinical development for thoracic malignancies.
Journal ArticleDOI
High Expression of Survivin Is Prognostic of Shorter Survival but Not Predictive of Adjuvant Gemcitabine Benefit in Patients with Resected Pancreatic Adenocarcinoma
Hao Xie,Wei Jiang,Wei Jiang,Wei Jiang,Shu-Yuan Xiao,Shu-Yuan Xiao,Shu-Yuan Xiao,Xiuli Liu,Xiuli Liu,Xiuli Liu +9 more
TL;DR: High expression of survivin is associated with shorter OS and PFS in patients with resected pancreatic adenocarcinoma after adjusting for other histopathological factors, however, survivin has no predictive value of adjuvant gemcitabine benefit.
Journal ArticleDOI
The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms.
Hao Xie,Junjia Liu,Siddhartha Yadav,Xavier M. Keutgen,Timothy J. Hobday,Jonathan R. Strosberg,Thorvardur R. Halfdanarson +6 more
TL;DR: PST stratified by grade and neoadjuvant or adjuvant therapy compared to SA was not associated with improved OS in patients with localized PanNEN, and should be used with caution until prospective data are available.
Journal ArticleDOI
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance).
Hao Xie,Jacqueline M. Lafky,Bruce W. Morlan,Philip J. Stella,Shaker R. Dakhil,Gerald G. Gross,William S. Loui,Joleen M. Hubbard,Steven R. Alberts,Axel Grothey +9 more
TL;DR: The combination of BEV and sorafenib as salvage therapy in heavily pretreated mCRC patients is tolerable and manageable, with evidence of promising activity.